Biotech Blueprint
Subscribe
Sign in
Home
Notes
This Week in Biotech
Startup Spotlight
Deep Dives
Consulting
Archive
About
Deep Dives
Latest
Top
Discussions
How mRNA Could Defeat Latent Viruses and Train Immunity Against Cancer
Moderna and BioNTech deploy AI-driven mRNA to target CMV, EBV, HSV, and personalized neoantigen cancer vaccines. These trials could redefine…
Oct 21
•
Katerina Roznik
and
The Biotech Capital Compass
6
5
The mRNA Revolution: Beyond COVID to Cancer, Flu & Herpes Vaccines
How Moderna and BioNTech are expanding from COVID into CMV, EBV, HSV, and next-gen flu, while scaling personalized cancer vaccines (part 1 of the mRNA…
Sep 18
•
Katerina Roznik
and
The Biotech Capital Compass
13
Sarepta, Elevidys, and the Future of AAV Gene Therapy
Part 2 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
Jul 29
•
Katerina Roznik
and
The Biotech Capital Compass
7
CRISPR in 2025: Clinical Use, Regulatory Pressure, and Future Promise
Part 1 of a mini-series on gene therapies, from the perspective of a scientist and an investor.
Jul 17
•
Katerina Roznik
6
Organoids, AI, and the FDA’s Move Away from Animal Models
Inside the FDA’s push to replace lab animals with human tissues & algorithms — with scientist Dr. Patrick Creisher.
May 29
•
Katerina Roznik
11
4
New contenders, old headwinds: global biotech looks to China
Western biotech faces a tougher funding climate, while Chinese firms move faster and aim higher, reshaping the industry’s global balance.
May 7
•
Katerina Roznik
and
Erin Mihealsick
13
3
What a global trade fight means for biotech
Biotech is already feeling the pinch from tariffs. What happens if pharmaceuticals are next?
Apr 7
•
Katerina Roznik
11
2
Psychedelic medicine as the new frontier in mental health care?
How changing political landscape and confirmation of RFK Jr. as HHS secretary may be paving the way for psychedelic therapies in mental health.
Feb 4
•
Katerina Roznik
6
Key drugs to keep an eye on in 2025
A deep dive into seven drugs with the potential for FDA approval in 2025, spanning from pain management to rare diseases.
Jan 4
•
Katerina Roznik
13
2
The future of mRNA: companies and trials to watch in 2025
Exploring the next wave of mRNA innovation in cancer, infectious diseases, and beyond. What will 2025 bring?
Dec 27, 2024
•
Katerina Roznik
26
The expanding landscape of GLP-1 drugs: What's next in the race for new treatments?
A deep dive into the latest GLP-1 clinical trials and the companies behind them
Sep 15, 2024
•
Katerina Roznik
6
1
Fauci's West Nile Virus infection highlights the need for vaccine and drug development
Limited progress in West Nile Virus research reveals gaps in our public health arsenal
Aug 27, 2024
•
Katerina Roznik
1
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
